Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via par-2–erk 1/2 pathway

HIGHLIGHTS

• What: In view of this, the authors focused on SECs and hypothesized that FXa inhibition might protect SECs and ameliorate hepatic IRI by suppressing FXa-PAR-2 signaling-induced inflammation. The authors focused on FXa, a protease-activated upstream of thrombin in the coagulation cascade and a selective inhibitor of edoxaban. The authors focused on ERK 1/2 and revealed that its activation was induced in the liver after hepatic IRI in_vivo and in the SECs after H/R stress.
• Who: Koki Maeda and colleagues from the Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.